Navigation Links
New Roche Chlamydia Test Approved for Use in European Union
Date:6/13/2008

Test offers more reliable detection of Chlamydia trachomatis, the most

commonly reported sexually transmitted disease in Europe.

PLEASANTON, Calif., June 13 /PRNewswire/ -- Roche announced today that its new test for detection of Chlamydia trachomatis has received CE Mark certification, allowing it to be sold for clinical use in the European Union. It is designed with a dual target approach to help ensure reliability of test results even when mutations occur in the bacteria's cryptic plasmid DNA. According to Eurosurveillance, a leading independent scientific journal, Chlamydia trachomatis is the most commonly reported sexually transmitted disease in Europe. Although it often causes no symptoms, Chlamydia can, if left untreated, lead to complications such as pelvic inflammatory disease or infertility in women.

"Unexpected mutations in the DNA of an infectious agent such as Chlamydia can disrupt laboratory testing and, by extension, proper treatment of patients," said Teresa L. Wright, M.D., O.B.E., Chief Medical Officer at Roche Molecular Diagnostics. "Because it is impossible to predict when these mutations will occur, we have designed this test to detect all Chlamydia strains that may cause a deletion in the cryptic plasmid, including the variant originally detected in Sweden in 2006."

Chlamydia trachomatis is often referred to as a "silent" sexually transmitted disease because approximately three quarters of infected women have no symptoms. Once detected, Chlamydia trachomatis can easily be treated with antibiotics. If left untreated, health risks can include chronic pelvic pain, pelvic inflammatory disease, potentially fatal ectopic pregnancy, increased risk of HIV infection if exposed, and infertility.

The highly sensitive and reliable COBAS(R) TaqMan(R) CT Test v2.0 simultaneously detects two targets within the C. trachomatis cryptic plasmid and genome target DNA. In contrast to earlier generation tests, the COBAS(R) TaqMan(R) CT Test v2.0 offers real-time PCR testing on the automated COBAS(R) TaqMan(R) 48 Analyzer. This automated platform can produce up to 48 tests per run and provide results in only 2.5 hours after sample preparation. Amplification and detection in a closed system combined with Roche's proprietary AmpErase enzyme and internal controls for each test help prevent cross contamination. This enhances test results integrity and quality control in laboratories.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information please contact:

Melinda Baker

Roche Molecular Diagnostics

Communications

Phone: 925-730-8379

email: melinda.baker@roche.com

Jessica Brillant

Roche Molecular Diagnostics

Communications

Phone : 925-730-8503

Email: jessica.brillant@roche.com


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves New Roche West Nile Virus Blood Screening Test
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
6. MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement
7. Nations Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract
8. Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX Systems to 10 instruments
9. Roche Extends Tender Offer for Ventana
10. Roche Offers Innovative Website Designed to Empower Cancer Patients
11. Neurochem reports results for third quarter of fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... for nominations seeking candidates for the Board of Commissioners. Individuals interested in volunteer ... and experience with diversity of clinical practice settings and across allied health to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in Orange ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:2/11/2016)... ... 11, 2016 , ... Duterte Insurance Group, serving the families ... new charity campaign to raise funds for Ronald McDonald House Charities. On behalf ... . , Ronald McDonald House (RMH) is an internationally renowned nonprofit organization which ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical Group (Be ... of Old Town at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well ... medical care in the convenience of their homes, offices or at the practices’ local ...
(Date:2/11/2016)... CO. (PRWEB) , ... February 11, 2016 , ... ... people have become more actively engaged in health and wellness best practices in ... importance of riding this trend. February is American Heart Month, which acts as ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- AfterPill.com is reporting that this week,s Centers for Disease ... who are at risk of unintended pregnancy impacts 43 ... the risks of unprotected sex in particular.  ... the Guttmacher Institute, there are 43 million women in ... have sex without the intention of becoming pregnant.  Despite ...
(Date:2/11/2016)... 11, 2016  Proliant Biologicals is proud to announce ... (BSA) manufacturing facility.  The facility is located on the ... in Feilding. Boone , Iowa.  ... duplicate the systems in the U.S. facility, with critical ... U.S. installations.  --> Boone ...
(Date:2/11/2016)... , Feb. 11, 2016 Brain Cancer ... treatment method at West Cancer Center . ... fields to inhibit cancer cell replication causing death of ... than a decade to show a significant extension in ... (GBM) patients. Currently, West Cancer Center is the only ...
Breaking Medicine Technology: